Case report of three patients with end-stage recurrent glioblastoma treated with meldonium.

ABSTRACT:

Background

Glioblastoma is the most aggressive primary brain tumor in adults. The prognosis is still very poor with a median survival time less than a year. A growing body of data supports the role for fatty acid oxidation (FAO) in the aggressive behavior of glioblastoma. We have previously shown that meldonium, an orally active compound that impairs FAO, caused significant growth reduction of glioblastoma in mice. Here, we report three cases of experimental meldonium-containing therapy in end-stage recurrent glioblastoma patients.

Methods

Three end-stage glioblastoma patients, who had second relapse tumor progression after standard of care therapy, received 500 mg meldonium twice a day on the top of the existing therapy regimen. Tolerability and treatment outcomes were moni

SUBMITTER: Bien-Moller S 

PROVIDER: S-EPMC12037855 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature